ReviewInternational journal of nanomedicine2025
Macrophage-Targeted Nanomedicine for the Treatment of Atherosclerosis.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Macrophage reprogramming through scavenger receptor-guided and cathepsin B-triggered nanodelivery: from intracellular mechanisms to translational applications.Frontiers in immunology · 2026Review
- Homocysteine promotes ferroptosis through NCOA4-mediated ferritinophagy in THP-1 macrophages.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular and cerebrovascular diseases are the leading causes of mortality worldwide, with atherosclerosis being the primary etiology. Despite its prevalence, atherosclerosis remains inadequately controlled by conventional therapeutic interventions. The unique physicochemical properties of nanomedicine offer new hope for the treatment of atherosclerosis. Macrophages are now understood to play a pivotal role in the progression of atherosclerosis, acting as both pathogenic factors and potential therapeutic targets. The inherent plasticity of macrophages significantly influences disease progression, suggesting that modulating macrophage function or abundance could provide a viable strategy to intervene in the atherosclerotic process. This review comprehensively examines the targeted delivery and controlled release of nanoparticles, providing an in-depth analysis of both passive and active targeting strategies, as well as the controlled release of therapeutic agents in response to the specific microenvironment of atherosclerotic plaques and external stimuli such as light and sound. The role of biomimetic nanomedicines in the treatment of atherosclerosis, primarily those utilizing macrophage membrane coatings and exosomes, is discussed. Finally, the current challenges facing nanomedicine in atherosclerosis treatment are analyzed, emphasizing the need for future research to investigate its mechanisms of action in depth and optimize related strategies to harness its therapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.